Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
Avantor's (AVTR) New Tie-Up to Improve Lab Inventory Management
by Zacks Equity Research
Avantor's (AVTR) latest partnership is expected to significantly optimize labs' inventory management and the overall workflow.
Intuitive Surgical (ISRG) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Intuitive Surgical (ISRG) outperforms the industry and the S&P 500 Index due to its strength in robotics.
Here's Why Investors Should Add Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on continued procedure recovery, solid execution and increasing traction around innovations.
3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
QIAGEN (QGEN) Expands Enzyme Offering to Aid Laboratory
by Zacks Equity Research
QIAGEN is a one-stop shop for all research needs, including solutions for sample preparation, automation and bioinformatics with enzyme offering expansion.
National Vision (EYE) Plans to Open New Stores Amid Macro Woes
by Zacks Equity Research
National Vision (EYE) plans to continue executing core growth initiatives and further investing in competitive advantages.
Abbott (ABT) Expands in Electrophysiology With New FDA Nod
by Zacks Equity Research
Abbott (ABT) notes that using TactiFlex catheter can lead to reduced procedure times and better safety compared to the company's previous generation catheters.
3 Reasons to Hold Inspire Medical (INSP) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inspire Medical (INSP) on the back of its product innovations.
BD's (BDX) Latest Product Launch to Boost Research Outcome
by Zacks Equity Research
BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting and allow researchers to answer complex biological questions.
Hologic (HOLX) Gets FDA Nod for Multiplexed Respiratory Test
by Zacks Equity Research
Hologic's (HOLX) Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is done using the fully-automated, high-throughput Panther Fusion system.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.
Here's Why You Should Retain Humana (HUM) in Your Portfolio
by Zacks Equity Research
Humana (HUM) remains well-poised for growth, attributable to a growing customer base, numerous contract wins and solid cash-generating abilities.
Abbott's (ABT) Assert-IQ Cardiac Monitor Receives FDA Approval
by Zacks Equity Research
Abbott's (ABT) latest approval adds to its line-up of remote patient management and treatment tools that can support doctors more effectively.
What's in the Cards for Medtronic (MDT) in Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) is likely to have prioritized its R&D investments, which might get reflected in the fiscal Q4 results.
STERIS (STE) Continues to Face Dull Dental Sales, Margin Woes
by Zacks Equity Research
STERIS (STE) competes for pharmaceutical, research and industrial customers against several large companies that have robust product portfolios and global reach.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Veeva Systems' (VEEV) New Launch to Improve Patient Outcomes
by Zacks Equity Research
Veeva Systems' (VEEV) new offering is expected to facilitate effective engagement with customers and KOLs for improved patient journeys.
Edwards Lifesciences' (EW) TAVR Study Outcome Favorable
by Zacks Equity Research
Edwards Lifesciences' (EW) latest findings of the study confirm the value of the Edwards Benchmark programme for standardizing clinical pathways for patients undergoing TAVR in Europe.
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) on its strong execution of strategies, disciplined cost management and revenue timing.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
BD's (BDX) New FDA Approval to Improve MRSA Diagnostics
by Zacks Equity Research
BD's (BDX) receipt of the latest FDA approval is likely to improve laboratory workflow.
Medtronic's (MDT) Global Market Share Strong, FX Headwind Stays
by Zacks Equity Research
Within cardiac rhythm management, Medtronic's (MDT) pacing business continues to outperform the market, banking on strong global growth of its Micra leadless pacemaker family.
LabCorp (LH) Expands Laboratory Relationship With New Pact
by Zacks Equity Research
LabCorp's (LH) recent partnership will expand healthcare access, offer advanced diagnostic tools and guarantee that both patients and doctors can afford the treatments they get.
NextGen (NXGN) Q4 Earnings Top Estimates, Revenues Surge Y/Y
by Zacks Equity Research
NextGen's (NXGN) fourth-quarter fiscal 2023 results reflect strength in both its revenue sources.